Last reviewed · How we verify
Albiglutide 50 mg
Albiglutide 50 mg, marketed by GlaxoSmithKline, is a GLP-1 receptor agonist with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and mechanism of action, which differentiates it from other antidiabetic treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | Albiglutide 50 mg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus (PHASE3)
- A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects (PHASE4)
- An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects (PHASE4)
- Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus (PHASE2)
- Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects (PHASE4)
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus (PHASE4)
- A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects (PHASE4)
- A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albiglutide 50 mg CI brief — competitive landscape report
- Albiglutide 50 mg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI